	ICIVIJE DISCLOSURE FO	KIVI	
Date:	6/2/2022	6/2/2022	
Your Name:	Wojciech MYDLARZ	Wojciech MYDLARZ WJOLARZ	
Manuscript Title: Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer			
Manuscript Number (if l	known): 161400-JCI-CMED-1		
content of your manuscr affected by the content indicate a bias. If you are The author's relationship epidemiology of hyperte that medication is not m	arency, we ask you to disclose all relationships/activities ript. "Related" means any relation with for-profit or not of the manuscript. Disclosure represents a commitme re in doubt about whether to list a relationship/activity ps/activities/interests should be defined broadly. For eaction, you should declare all relationships with manufactioned in the manuscript. It all support for the work reported in this manuscript whe past 36 months.	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning	of the work	
1 All support for the present manuscript (e.g., funding, provision of study materials,	None This project was funded entirely by the NIH intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH	

medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months None 2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or \boxtimes None licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	_ 1
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None None	
Plea		t to the following statement to indicate your agreeme	

Date:	6/2/2022
Your Name:	Evrim B. Turkbey Evrim B. Turkbey
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1
• • • • • • • • • • • • • • • • • • • •	re ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This project was funded entirely by the NIH intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	✓ None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea		t to the following statement to indicate your agreement to a second and the secon	

Date:	6/3/2022
Your Name:	Jennifer L. Marte
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

ľ		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None project was funded entirely by the NIH amural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

T certify that I have answered every question and have not aftered the wording

Dat	e:	6/2/2022		
Your Name:		Chyi-Chia Richard Lee	: Mil Lee 6/02/2022	
Mar	nuscript Title:		Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer	
Ma	nuscript Number (if	known): 161400-JCI-CMED-1		
con affe indi The epic tha	ected by the content icate a bias. If you a demiology of hypert it medication is not re	rarency, we ask you to disclose all relationships/activity or the manuscript. Disclosure represents a commitmer of the manuscript. Disclosure represents a commitmer of the manuscript. Disclosure represents a commitmer of the manuscript of the manuscript of the manuscript. The manuscript of the manuscript of the past 36 months.	not-for-profit third parties whose interests may be ent to transparency and does not necessarily y/interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning		
1	All support for the present manuscript (e.g.,	None	All research related patient care, correlative	
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This project was funded entirely by the NIH intramural research program	studies and acquisition of drug was through the NIH Click the tab key to add additional rows.	
	funding, provision of study materials, medical writing, article processing charges, etc.)	intramural research program	Studies and acquisition of drug was through the NIH Click the tab key to add additional rows.	
2	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		Studies and acquisition of drug was through the NIH Click the tab key to add additional rows.	

Date:			6/2/2022			
Your Name:			Antonios Papanicolau-Sengos			
X	<u>′</u>					
An	tonios Papanicolau-Sengos					
Ma	nuscript Title:		Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer			
Ma	nuscript Number (if k	nown):	161400-JCI-CMED-1			
cor affo ind The epi tha	etent of your manuscri ected by the content o icate a bias. If you are a author's relationships demiology of hyperter t medication is not me	pt. "Rela f the man e in doubt s/activition nsion, you entioned	ated" means any relation with for-profit or no nuscript. Disclosure represents a commitme t about whether to list a relationship/activity es/interests should be defined broadly. For e u should declare all relationships with manuf in the manuscript.	/interest, it is preferable that you do so.		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	This pro	one Dject was funded entirely by the NIH Ural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH		

		relationship of maleute home (add for all medical)	
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials, medical writing,	This project was funded entirely by the NIH intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH
	article processing charges, etc.)		Click the tab key to add additional rows.
	No time limit for this item.		
		Time frame: past 36 month	s
2	Grants or contracts from	None	
	any entity (if not indicated in item		
	#1 above).		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	☐ None I own various cryptocurrencies that are unrelated to this publication.	
Plea ⊠		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

6/2/2022

Date:

You	ır Name:		Andrew Sinkoe			
Manuscript Title:			Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer			
Manuscript Number (if known):			161400-JCI-CMED-1			
In the interest of transparency, we content of your manuscript. "Relai affected by the content of the man indicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned in			nted" means any relation with for-profit or nonuscript. Disclosure represents a commitment about whether to list a relationship/activity es/interests should be defined broadly. For a should declare all relationships with manufaction in the manuscript.	/interest, it is preferable that you do so.		
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This pro	one oject was funded entirely by the NIH ural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This pro	oject was funded entirely by the NIH	studies and acquisition of drug was through the NIH Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This pro intramu	oject was funded entirely by the NIH ural research program	studies and acquisition of drug was through the NIH Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

T certify that I have answered every question and have not aftered the wording

Da	ate:		5/2/2022			_
Yo	our Name:	يل	ames Gulley	Jan Ga	-	
Ma	anuscript Title:			oepitope-specific imm de in HPV-unrelated h	unity following neoadjuvant PD-L1 and ead and neck cancer	
Ma	anuscript Number (if kr	nown):1	161400-JCI-C	MED-1		_
aff inc	ntent of your manuscrip fected by the content of dicate a bias. If you are e author's relationships idemiology of hyperten	ipt. "Relate of the manu e in doubt a os/activities, nsion, you s	ed" means any r script. Disclosu bout whether t /interests shoul hould declare a	relation with for-profit or range represents a commitm of list a relationship/activited be defined broadly. For all relationships with manual series with manual series are series.	ies/interests listed below that are related to the not-for-profit third parties whose interests may be ent to transparency and does not necessarily y/interest, it is preferable that you do so. example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	at medication is not me		•			
	item #1 below, report a me for disclosure is the			ported in this manuscript v	without time limit. For all other items, the time	
	1	Name all e	ntities with wh	om you have this	Specifications/Comments (e.g., if payments were	e
				one (add rows as needed)		
			p or indicate no	•	made to you or to your institution)	
1	All support for the present	relationshi	p or indicate no Time frame	one (add rows as needed) e: Since the initial planning	made to you or to your institution)	
1	All support for the present manuscript (e.g., funding, provision of study materials,	relationshi	p or indicate no Time frame	one (add rows as needed)	made to you or to your institution)	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	relationshi None Intramura	Time frame Time frame I research progr	e: Since the initial planning ram of the NIDCD, NIH	made to you or to your institution) of the work All research related patient care, correlative studies and acquisition of drug was through the	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None Intramura Drug for the	Time fram Time fram I research programs study was programs study was programs and the study was prog	e: Since the initial planning	made to you or to your institution) of the work All research related patient care, correlative studies and acquisition of drug was through the	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None Intramura Drug for the	Time fram Time fram I research programs study was programs study was programs and the sequencing for the s	e: Since the initial planning ram of the NIDCD, NIH ram of the NCI, CCR, NIH rovided by Merck KGaA this study was funded by	All research related patient care, correlative studies and acquisition of drug was through the NIH	, , , , , , , , , , , , , , , , , , , ,
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Intramura Drug for the	Time fram Time fram I research programs study was programs and the search programs and the search programs are sequencing for the search programs are search programs.	e: Since the initial planning ram of the NIDCD, NIH ram of the NCI, CCR, NIH rovided by Merck KGaA	All research related patient care, correlative studies and acquisition of drug was through the NIH	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Intramura Drug for the Genomic solumnunity for the contract of	Time fram Time fram I research programs study was programs and the sequencing for the s	e: Since the initial planning ram of the NIDCD, NIH ram of the NCI, CCR, NIH rovided by Merck KGaA this study was funded by	All research related patient care, correlative studies and acquisition of drug was through the NIH	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Drug for this study was provided by Merck KGaA	
13	Other financial or non-financial interests	[⊠] None	
Plea		to the following statement to indicate your agreeme answered every question and have not altered the wo	

3

[Date:	6/2/2022		
γ	our Name:	Jeffrey Schlom	Say LOVen	
N	Manuscript Title:	Enhanced neoe TGF-b blockade	oitope-specific imm	nunity following neoadjuvant PD-L1 and nead and neck cancer
N	lanuscript Number (if knowr			
a ir	ffected by the content of the ndicate a bias. If you are in do	manuscript. Disclosure	represents a commitmo it a relationship/activit	ies/interests listed below that are related to the not-for-profit third parties whose interests may be ent to transparency and does not necessarily y/interest, it is preferable that you do so.
th	nat medication is not mention	ed in the manuscript.	eiationships with manu	example, if your manuscript pertains to the facturers of antihypertensive medication, even if
In fr:	item #1 below, report all sup ame for disclosure is the past	port for the work report 36 months.	ed in this manuscript v	vithout time limit. For all other items, the time
	Name relation	all entities with whom onship or indicate none	you have this (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Si	nce the initial planning	of the work
1	present manuscript (e.g., Intra	Time frame: Si None mural research program		All research related patient care, correlative
1	present manuscript (e.g., funding, provision of study materials,	None mural research program	of the NIDCD, NIH	All research related patient care, correlative studies and acquisition of drug was through the NIH
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing Intra	None mural research program mural research program	of the NIDCD, NIH	All research related patient care, correlative studies and acquisition of drug was through the NIH
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) Intra Drug Geno	None mural research program	of the NIDCD, NIH of the NCI, CCR, NIH	All research related patient care, correlative studies and acquisition of drug was through the
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None mural research program mural research program for this study was provice mic sequencing for this senityBio	of the NIDCD, NIH of the NCI, CCR, NIH	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None mural research program mural research program for this study was provice mic sequencing for this senityBio	of the NIDCD, NIH of the NCI, CCR, NIH ed by Merck KGaA itudy was funded by	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Mone mural research program mural research program for this study was provic mic sequencing for this s inityBio	of the NIDCD, NIH of the NCI, CCR, NIH ed by Merck KGaA itudy was funded by	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
3	Patents planned, issued or pending	None
	Participation on a Data Safety Monitoring Board or Advisory Board	None None
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Drug for this study was provided by Merck KGaA	
13	Other financial or non-financial interests	None Non	
Pleas	se place an "X" next	to the following statement to indicate your agreemen	nt:
	I certify that I have	answered every question and have not altered the word	ding of any of the questions on this form

3

Date:	6/2/2022	
Your Name:	Patrick Soon-Shiong Pairle	
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer	
Manuscript Number (if known):	161400-JCI-CMED-1	
content of your manuscript. "Rela affected by the content of the man indicate a bias. If you are in doubt The author's relationships/activities	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if	

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Intramural research program of the NIDCD, NIH Intramural research program of the NCI, CCR, NIH Drug for this study was provided by Merck KGaA Genomic sequencing for this study was funded by ImmunityBio	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
		Time frame: past 36 month	is
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

	Name all entities with whom you have this relationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
Stock or stock options	None	
Receipt of equipment, materials, drug medical writing gifts or other services		
Other financia non-financial interests	al or [X] None	
	" next to the following statement to indicate your agreen	
	" next to the following statement to indicate your agreen have answered every question and have not altered the v	

5/25/2022

Date:

Your Name:		Clint Allen CAPULEN			
Manuscript Title:		Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer			
Ma	nuscript Number (if l	known):	161400-JCI-	CMED-1	
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned		rt for the work reported in this manuscript without time limit. For all other items, the time			
				whom you have this none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time fra	me: Since the initial plannir	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH NIE	one DCD intramural I intramural reso as provided by I		Funding for sequencing was provided by ImmunityBio Click the tab key to add additional rows.
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NIH NIE	DCD intramural	earch program	ImmunityBio Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NIH NIE NIH NC Drug w	DCD intramural	earch program Merck KGaA	ImmunityBio Click the tab key to add additional rows.

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None Drug for this study was provided by Merck KGaA	
13	Other financial or non-financial interests	None Non	
Plea ⊠	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	6/2/2022
Your Name:	Andrew Nguyen]
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.


		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None
13	Other financial or non-financial interests	None
Plea 🖂		et to the following statement to indicate your agreement:

Date:		6/2/2022							
Your Name:		Wiem Lassoued	wey	(3/2/2022	_			
Manuscript Title:			Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer						
Mar	nuscript Number (if k	nown):	161400-JCI-CMED-1						
con affe indi The epic that	tent of your manuscricted by the content ocate a bias. If you are author's relationship demiology of hyperters medication is not me	ipt. "Rela of the man e in doubt as/activition ision, you entioned	nted" means any relinuscript. Disclosure about whether to less/interests should ushould declare all in the manuscript.	ation with for-profit or no represents a commitment ist a relationship/activity, be defined broadly. For e relationships with manuf	t-for-prof at to trans /interest, i xample, if acturers o	s listed below that are related to the it third parties whose interests may be parency and does not necessarily it is preferable that you do so. Your manuscript pertains to the fantihypertensive medication, even if			
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.								
			l entities with who ship or indicate nor	m you have this se (add rows as needed)		ations/Comments (e.g., if payments were	2		
2000	NEW YORK OF STREET	DE ALLES							
			Time frame:	Since the initial planning	of the wo	rk			
1	All support for the	[□] No	Time frame: one	Since the initial planning	of the wo	rk			
1	present manuscript (e.g., funding, provision of study materials, medical writing,	This pro		tirely by the NIH	All resear studies a NIH	rch related patient care, correlative nd acquisition of drug was through the			
1	present manuscript (e.g., funding, provision of study materials,	This pro	one oject was funded en	tirely by the NIH	All resear studies a NIH	rch related patient care, correlative			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This pro	one oject was funded en ural research progra	tirely by the NIH	All resear studies a NIH	rch related patient care, correlative nd acquisition of drug was through the			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	This pro intramu	one oject was funded en ural research progra	tirely by the NIH m	All resear studies a NIH	rch related patient care, correlative nd acquisition of drug was through the			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	



		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
11	Stock or stock options	None					
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None					
13	Other financial or non-financial interests	None					
Plea	Please place an "X" next to the following statement to indicate your agreement: certify that have answered every question and have not altered the wording of any of the questions on this form.						

Date:	6/2/2022
Your Name:	Steven Hong
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None This project was funded entirely by the NIH intramural research program Time frame: past 36 months	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/2/2022
Your Name:	Xinping Yang Xiping Yay
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None This project was funded entirely by the NIH intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	X
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None

		ne all entities with whom you have this stionship or indicate none (add rows as needed) Specifications/Comments (a made to you or to your inst		
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			

12/13/2021 ICMJE Disclosure Form

6/2/2022

Date:

2410.	9/2/2022	
Your Name:	[Cem Sievers	
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer	
Manuscript Number (if known):	161400-JCI-CMED-1	
In the interest of transparency, w	e ask you to disclose all relationships/activities/interests listed below that are related to the	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None This project was funded entirely by the NIH	All research related patient care, correlative
	funding, provision of study materials, medical writing,	intramural research program	studies and acquisition of drug was through the NIH
	article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 month	ns .

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None □	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

6/2/2022
Rodney Taylor
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

ľ		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None project was funded entirely by the NIH amural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	6/2/2022
Your Name:	YVETTE ROBBINS
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	intramural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None ■	

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	6/3/2022
Your Name:	Matthew Pierce
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

ľ		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None project was funded entirely by the NIH amural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

TGF-b blockade in HPV-unrelated head and neck cancer

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and

6/2/2022

Jay Friedman

Manuscript Number (if known): 161400-JCI-CMED-1					
con affe indi The epic that	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	1 '	ject was funded entirely by the NIH ral research program	All research related patient care, correlative studies and acquisition of drug was through the NIH	
			Time frame: past 36 month	S	
2	Grants or contracts from any entity (if not indicated in item #1 above).	No	ne		
3	Royalties or licenses	⊠ No	ne		

Date:

Your Name:

Manuscript Title:

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	■ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Night RZ 200 J.

Date:	6/2/2022
Your Name:	Nyall London
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

				-
			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present		None	
	manuscript (e.g., funding, provision of study materials, medical writing,		project was funded entirely by the NIH amural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH
	article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.
			Time frame: past 36 month	s
2	Grants or contracts from		None	
	any entity (if not indicated in item #1 above).	Mei	rck	N. London receives research funding from Merck regarding HPV-related sinonasal tumors unrelated to this manuscript

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group,			
	paid or unpaid			
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	\boxtimes	None	
13	Other financial or non-financial	\boxtimes	None	
	interests			
Please place an "X" next to the following statement to indicate your agreement:				
\boxtimes	I certify that I have	answe	ered every question and have not altered the wo	ording of any of the questions on this form.

Date:	6/2/2022
Your Name:	Jason Redman
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This project was funded by the intramural research program of the NCI, CCR, NIH Drug for this study was provided by Merch KGaA Genomic sequencing for this study was funded by ImmunityBio	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 month None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Jason M. Redman

Date:	6/3/2022
Your Name:	Arjun Joshi
Manuscript Title:	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer
Manuscript Number (if known):	161400-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None project was funded entirely by the NIH amural research program	All research related patient care, correlative studies and acquisition of drug was through the NIH Click the tab key to add additional rows.		
2	Grants or contracts from any entity (if not indicated in item #1 above).		None			
3	Royalties or licenses		None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	ere
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Please place an "X" next to the following statement to indicate your agreement:					